Olidia PLLA (Poly L Lactic Acid) Dermal Filler 365 mg

Olidia

Injectable collagen-stimulating dermal filler (medical device)

Poly-L-lactic acid (PLLA) biodegradable injectable dermal filler for facial volume restoration and wrinkle correction

CE Approved injectable poly L Lactic acid dermal filler (CE marking for use as a collagen Stimulating medical device in the European market).
Approved by the Korean Ministry of Food and Drug Safety (MFDS) as a PLLA dermal filler; some sources reference device classification as graft/prosthesis (e.g. Class 4, classification B04230.02).
Manufactured by PRP Life Science in South Korea with ISO 13485 certification and multiple GMP/quality certificates listed in trade documentation.
Uses PLLA as the main active ingredient, a biodegradable synthetic polymer with a long history of use in medical devices and recognised by the U.S. FDA as an approved material in several indications (e.g. absorbable sutures and certain soft Tissue augmentation devices).
Clinical data cited by distributors (e.g. trial NCT04568902) report 82% volume retention at 25 Month follow Up and a 143% increase in type I collagen at 6 months after treatment, supporting long Term performance claims.
Olidia is marketed and regulated as a CE Marked injectable medical device rather than as a licensed medicinal product; it does not have an MHRA medicinal product licence entry and is instead subject to medical device regulatory frameworks.

CE Approved injectable poly L Lactic acid dermal filler (CE marking for use as a collagen Stimulating medical device in the European market).
Approved by the Korean Ministry of Food and Drug Safety (MFDS) as a PLLA dermal filler; some sources reference device classification as graft/prosthesis (e.g. Class 4, classification B04230.02).
Manufactured by PRP Life Science in South Korea with ISO 13485 certification and multiple GMP/quality certificates listed in trade documentation.
Uses PLLA as the main active ingredient, a biodegradable synthetic polymer with a long history of use in medical devices and recognised by the U.S. FDA as an approved material in several indications (e.g. absorbable sutures and certain soft Tissue augmentation devices).
Clinical data cited by distributors (e.g. trial NCT04568902) report 82% volume retention at 25 Month follow Up and a 143% increase in type I collagen at 6 months after treatment, supporting long Term performance claims.
Olidia is marketed and regulated as a CE Marked injectable medical device rather than as a licensed medicinal product; it does not have an MHRA medicinal product licence entry and is instead subject to medical device regulatory frameworks.

Poly-L-lactic acid (PLLA) biodegradable injectable dermal filler for facial volume restoration and wrinkle correction

Description

Olidia PLLA is an injectable poly-L-lactic acid (PLLA) dermal filler and collagen stimulator developed by PRP Life Science (PRPscience) in South Korea. Supplied as a sterile, absorbable lyophilised PLLA powder (typically 365 mg per vial) for reconstitution, it is injected into the dermis or subcutaneous tissue to restore facial volume, correct contour defects and smooth moderate to severe wrinkles such as nasolabial folds and marionette lines. Olidia works by stimulating neocollagenesis: PLLA microparticles trigger fibroblasts to produce new collagen, creating a gradual, natural-looking increase in dermal volume and improved skin elasticity that can last 18–36 months after a treatment course. The formulation combines PLLA with carboxymethylcellulose (CMC) and mannitol (PSPCM technology) to optimise particle suspension, injection performance and safety. Olidia is CE-marked and approved by the Korean Ministry of Food and Drug Safety (MFDS) as a collagen-stimulating dermal filler for adult patients, and is manufactured in ISO 13485-certified facilities. It is supplied internationally through specialist aesthetic distributors and online wholesale platforms, including Derma Filler Ltd in the UK.

Bnefits

Biodegradable, biocompatible poly-L-lactic acid (PLLA) dermal filler that stimulates the body’s own collagen production rather than acting as a simple space-occupying gel.
Provides gradual, natural-looking restoration of facial volume and contour with progressive improvement in skin firmness and elasticity over several months.
Indicated for temporary improvement of moderate to severe nasolabial folds and other facial wrinkles and folds, as well as facial contour defects and volume loss.
Long-lasting results: distributor and clinical data sources report aesthetic effects persisting for approximately 18–36 months after a completed treatment course.
CE-marked and MFDS-approved collagen-stimulating dermal filler manufactured in South Korea in ISO 13485-certified facilities.
High particle uniformity (around 99% homogeneity within a defined 40–63 μm size range in many technical descriptions) designed for predictable 3D collagen scaffold formation.
Synthetic PLLA composition with long history of use in medical devices (including absorbable sutures) and no requirement for allergy skin testing prior to treatment according to manufacturer and distributor information.
Versatile treatment applications including nasolabial folds, marionette lines, midface volume, temples, chin, cheekbones and jawline contouring, and facial lipoatrophy, when used by trained professionals.
Supports a structured, protocol-based approach (typically 3–4 sessions spaced 4–6 weeks apart) that can be tailored to patient age, degree of volume loss and aesthetic goals.

Indications

Temporary improvement of moderate to severe nasolabial folds in adults by injection into the dermis or subcutaneous tissue.
Correction of shallow to deep facial wrinkles and folds, including marionette lines and other expression lines, in immune-competent adults.
Restoration of facial volume and correction of contour deficiencies in areas such as cheeks, temples, jawline, chin and cheekbones.
Treatment of facial contour defects and volume loss associated with ageing or lipoatrophy, as described in distributor and clinical marketing materials.
Use as a collagen-stimulating dermal filler in adults without contraindications, administered only by appropriately trained healthcare professionals in accordance with the official instructions for use.

Composition

Main active ingredient: Poly-L-lactic acid (PLLA) 365 mg per vial (lyophilised powder).
Key excipients (PSPCM technology): carboxymethylcellulose (CMC) and mannitol, providing suspension matrix and optimised particle behaviour.
PLLA characteristics: biodegradable, biocompatible aliphatic polyester polymer; particle size distribution typically reported around 40–63 μm for smooth injection and predictable collagen stimulation.
Device classification information from technical listings: injectable PLLA dermal filler, CE-approved; MFDS-approved graft/prosthesis-type device for soft-tissue augmentation (classification references such as Class 4 graft/prosthesis are given in some trade sources).
No additional preservatives, animal-derived proteins or human-derived components are listed in publicly available manufacturer and trade documentation.

Formulation

Sterile, absorbable lyophilised powder containing 365 mg poly-L-lactic acid (PLLA) with CMC and mannitol in a single-use glass vial.
Requires reconstitution with sterile diluent (e.g. sterile water for injection and, in some protocols, lidocaine) according to the manufacturer’s instructions before injection.
Injectable suspension for deep dermal or subcutaneous administration using needle or cannula techniques by trained professionals.
Collagen-stimulating mechanism: PLLA microparticles induce controlled fibroblast activation and neocollagenesis; newly formed collagen gradually replaces the resorbed particles, creating lasting volume and structural support.
Biodegradation: PLLA is metabolised over time via hydrolysis and is ultimately eliminated as carbon dioxide and water through normal physiological pathways.
Available dose variants referenced on the official Olidia site include 365 mg (subcutaneous layer), 243.4 mg and 121.7 mg formulations (subdermal layer), all based on the same PLLA + CMC + mannitol composition; the Derma Filler Ltd listing corresponds to the 365 mg dermal filler vial.

Packaging

Primary packaging: single glass vial containing 365 mg lyophilised PLLA-based powder (Olidia PLLA Dermal Filler).
Secondary packaging: 1 vial per box ("1 vial / 1 box" as per WEDERM and multiple distributor listings).
Typical pack labelling (from manufacturer and trade descriptions): product name (Olidia), main composition (PLLA + CMC + mannitol), dose (365 mg), country of origin (Republic of Korea), CE mark and MFDS approval references, and manufacturer details (PRP Life Science).
The Derma Filler Ltd online listing presents the product as a single Olidia dermal filler unit, using the manufacturer’s pack artwork image.

Usage

Professional use only: Olidia PLLA must be reconstituted and injected exclusively by licensed healthcare professionals trained in PLLA-based collagen-stimulating fillers and in accordance with local regulations and the official instructions for use.
Reconstitution: before administration the lyophilised PLLA powder is reconstituted with a specified volume of sterile diluent (e.g. saline, with or without local anaesthetic) and allowed to fully hydrate as per manufacturer guidance; exact diluent volumes and preparation steps are detailed in the IFU and are not comprehensively disclosed in public marketing copy.
Injection technique: the product is injected into the deep dermis or subcutaneous tissue using linear threading or similar implantation techniques, depending on indication and anatomical site, following manufacturer and training recommendations.
Typical treatment course (based on multiple distributor protocols): 3 treatment sessions at intervals of approximately 4–6 weeks; some sources describe 3 treatments at 1-month intervals, with occasional single-session use for mild cases.
Treatment areas commonly listed: nasolabial folds, marionette lines, cheeks, temples, jawline, chin, cheekbones and other regions of facial volume loss or contour deficiency; off-face use (e.g. hands) is described in some distributor and user reports but must be considered in line with local regulations and off-label use policies.
Post-treatment care (from manufacturer and clinic information): patients are often advised to avoid alcohol, smoking, hot baths or saunas and strenuous exercise for a certain period after treatment; they may be instructed to massage treated areas periodically to help distribute the product and reduce risk of nodules, following the injector’s protocol.
Use only in adults without contraindications; do not use in individuals under 18 years of age or in patients who do not meet the health criteria defined in the IFU.
Detailed preparation instructions, injection volumes per site, needle/cannula specifications and post-procedure massage protocols are provided in the manufacturer’s professional documentation and dedicated training materials, and are not fully reproduced in public-facing sources.

Contraindications

Not publicly listed in full in IFU form; however, several distributor and technical listings specify that Olidia PLLA should not be used in patients with:
– Low blood clotting (coagulopathy or significant bleeding disorders).
– Diabetes mellitus (particularly where wound healing is impaired), as cited among contraindications by at least one distributor.
– Active wounds, cuts, burns, infections or multiple skin lesions in the intended injection area.
– Oncological diseases (active malignancy), according to distributor contraindication lists.
– Known allergic or hypersensitivity reactions to lactic acid or any component of the product (e.g. PLLA).
Olidia is intended for immune-competent adults only and is not recommended for individuals under 18 years of age, as stated by several distributors.
Standard PLLA filler precautions also apply in clinical practice (e.g. caution or avoidance in pregnancy and breastfeeding, severe autoimmune disease, history of keloid or hypertrophic scarring, or active inflammatory skin disease at the injection site), but these broader categories are not all explicitly enumerated for Olidia in open-access manufacturer text and must be confirmed in the official instructions for use.

Adverse Effects

Injection-site reactions reported in clinic and distributor information include temporary redness, swelling, bruising, tenderness and pain at treated sites, typically resolving within a few days to about two weeks.
Some trade and clinic sources list additional common local effects such as firmness, lumps/bumps, itching and transient discolouration at or near injection sites.
Like other PLLA fillers, incorrect injection depth, preparation or aftercare may increase the risk of palpable or visible nodules and granulomas, including delayed-onset nodules; these risks are widely recognised for PLLA products and are emphasised in professional guidance and comparison articles.
Clinical and trade sources generally describe the overall complication rate as low when Olidia is used correctly by trained professionals, but precise frequency tables of adverse events for Olidia are not publicly available; detailed safety data, warnings and adverse reaction information are contained in the manufacturer’s IFU.

Storage Conditions

Store at room temperature, typically below 30°C, as specified consistently in multiple technical and trade listings.
Do not freeze the product; storage at sub-zero temperatures is explicitly contraindicated.
Protect from light where indicated in distributor storage instructions.
Keep out of the reach of children.
Do not incinerate or throw vials into fire after use.
Shelf-life information (e.g. 24 months from manufacture) is noted on some distributor listings; the exact expiry period and any additional storage requirements are defined in the manufacturer’s packaging and instructions for use.

Duration

Publicly available distributor and clinical marketing data report that Olidia PLLA treatments typically involve a series of about 3\u20134 sessions at 4\u20136 week intervals, with volumising and wrinkle-smoothing effects lasting approximately 18\u201336 months (2\u20133 years) after the completed course; one wholesale source cites clinical data (NCT04568902) showing around 82% volume retention at 25 months and a 143% increase in type I collagen at 6 months. Exact duration and retreatment intervals are determined by the treating professional based on the official instructions for use and individual patient response.

Onset

Multiple clinical marketing sources state that initial volume and contour improvements become apparent over approximately 4\u20138 weeks as new collagen forms, with some immediate effect from injection volume and a more pronounced, stable result emerging progressively over subsequent months.